Primary Objectives:
* To determine the acute and long-term outcomes of redo TAVR for the treatment of BVF affecting TAVs
* To determine the factors which are associated with the acute and long-term outcomes of redo TAVR
Age
18–105
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
BVF of a TAV (either Medtronic or Edwards) requiring redo TAVR
You may not be if
BVF due solely to paravalvular regurgitation
Active endocarditis
Untreated acute valve thrombosis
Life-expectancy less than 1-year
Subject is less than legal age of consent, legally incompetent, or otherwise vulnerable
Participating in another study that may influence the outcome of this study
Clareo Health | REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
